Annovis Bio Dirección
Dirección controles de criterios 2/4
El CEO de Annovis Bio es Maria Maccecchini , nombrado en May 2008, tiene una permanencia de 16.5 años. compensación anual total es $2.15M, compuesta por 31.1% salario y 68.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 8.41% de las acciones de la empresa, por valor de $7.72M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 8.8 años, respectivamente.
Información clave
Maria Maccecchini
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 31.1% |
| Permanencia del CEO | 16.5yrs |
| Participación del CEO | 8.4% |
| Permanencia media de la dirección | 1.3yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Annovis Bio To Continue Alzheimer's Disease Clinical Trials
Oct 17Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Sep 27Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$43m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$2m | US$668k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$3m | US$636k | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$9m | US$510k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$1m | US$420k | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$1m |
| Dec 31 2019 | US$120k | US$120k | -US$991k |
| Sep 30 2019 | n/a | n/a | -US$958k |
| Jun 30 2019 | n/a | n/a | -US$841k |
| Mar 31 2019 | n/a | n/a | -US$715k |
| Dec 31 2018 | US$155k | US$120k | -US$714k |
Compensación vs. Mercado: La compensación total de Maria($USD2.15M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.63K).
Compensación vs. Ingresos: La compensación de Maria ha sido consistente con los resultados de la empresa en el último año.
CEO
Maria Maccecchini (73 yo)
16.5yrs
Permanencia
US$2,145,852
Compensación
Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 8.41% $ 7.7m | |
| Chief Business Officer & Director | less than a year | US$135.43k | 0.47% $ 429.9k | |
| Senior Vice President of Research & Development | 2.8yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Operations | 2.8yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Operations | 1.3yrs | sin datos | sin datos | |
| Head of Quality | less than a year | sin datos | sin datos | |
| Senior Vice President of Statistics | less than a year | sin datos | sin datos |
1.3yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de ANVS no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 16.5yrs | US$2.15m | 8.41% $ 7.7m | |
| Chief Business Officer & Director | 8.8yrs | US$135.43k | 0.47% $ 429.9k | |
| Independent Chairman of the Board | 10.8yrs | US$153.92k | 12.56% $ 11.5m | |
| Chief Medical Advisor & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.8yrs | sin datos | sin datos | |
| Independent Director | 3.6yrs | US$143.92k | 0.056% $ 51.3k | |
| Chairman of Scientific Advisory Board | 7.8yrs | sin datos | sin datos | |
| Independent Director | 9.8yrs | US$135.43k | 0.050% $ 46.2k |
8.8yrs
Permanencia media
71.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ANVS se considera experimentada (8.8 años de antigüedad promedio).